Please ask me if I need to explain this Post 2 question in details
Post 2 (Please refer to page 3 and 4) 1. I have chosen below student’s peer's post and briefly clarify why you choose this health issue to respond to. (Around 100 words) 2. Provides feedback/comments on the peer's post such as the peer's topic and methods used for developing the research question, with references support. (150-200 words) 3. Provides suggestions and recommendations. (150-200 words) Assessment task 2: Discussion board assessment Assessment description: For this unit, you will be completing one discussion board assessment. In this assessment, you will be creating an original post and a reply post to your peers based on a healthcare topic that interests you. · Weight: 50% · Length: 2 x 500 words discussion posts · Due date: 6th August 2023, 23:30:00 ACST · Learning Outcomes: 1, 2, 3, 4 *Please note that you will not be able to view other students’ submissions (and therefore peer review their work) until you have submitted your discussion board post. Assessment instructions Using what you have learned in modules 1, 2 & 3. create an original post explaining a research question you have developed on a healthcare challenge in your own area. The original post should explain: (1) what the healthcare challenge is and (2) include a breakdown of the PICO or PICo that you have used to create your research question. Instructions for original post [post 1] (500 words): 1. Clearly and succinctly summarize the research topic in your own healthcare area that you want to address and justify why research is useful for addressing the clinical problem (100-150 words) 2. Develops an appropriate research question using the PICO or PICo framework and explains which model was selected and why (100-150 words) 3. Discuss the most suitable forms of evidence (e.g., evidence from qualitative study, evidence from randomized control trials, or evidence from systematic reviews) to answer the research question you proposed and justify why with references support (200- 300 words) Instructions for responding to one peer's post [post 2]: (500 words) 1. Choose one peer's post and briefly clarify why you choose this health issue to respond to. (Around 100 words) 2. Provides feedback/comments on the peer's post such as the peer's topic and methods used for developing the research question, with references support. (150-200 words) 3. Provides suggestions and recommendations. (150-200 words) Please note: For both two posts, please 1. Submit directly to the discussion board (no attachments please) 2. 10 References (APA 7th reference) should be within last 5 years should be included, from 2018 and onward. 3. Your reference list is not included in the word count. 4. 1st person is acceptable in the discussion board assessment. 5. Please reference all your claims – including in the evaluation section, if necessary. If you are including information from a journal article/textbook etc. then you must reference it. 6. You will only be able to review and respond to your peer’s posts once you have submitted your own. Marking Rubric Please access the marking rubric to ensure that you are maximising your marks in your submission. I have chosen below student’s peer's post and briefly clarify why you choose this health issue to respond to. (Around 100 words) Provides feedback/comments on the peer's post such as the peer's topic and methods used for developing the research question, with references support. (150-200 words) Provides suggestions and recommendations. (150-200 words) ASSESSMENT 2 I have used the PICO framework to examine whether psychedelics are a better treatment for depression and anxiety through quantitative research that uses numerical data and statistical methods to test hypothesis, measure outcomes and compare the use of mental health treatments. This topic is of great interest to me as I was recently doing my mental health placement and that experience has left me with so much curiosity in mental health. I have witnessed many patients who did not improve in their mental state being prescribed more stronger medication to sedate them. This to me seems to be a temporary measure which helps and sometimes does not so I thought the above question, putting aside all the stigma associated with psychedelic use might be an opportunity to look deeper into other options which might help reduce this health issue in our communities. According to Beyond Blue statistics, 1 in 13 people in Australia experienced depression symptoms in 2020-21 (1.5 million people) and 1 in 6 people in Australia experienced anxiety symptoms in 2020-21(Beyond blue). Furthermore, the Australian Bureau of statistics states that over 2 in 5 Australians aged 16-85 years (8.6 million people) had experienced a mental health disorder at some time in their life (ABS, 2021). P-Mental health I-Psychedelic drugs C-Antidepressants O-Treatment of depression and anxiety Research Question - In mental health are psychedelics better treatment for depression and anxiety symptoms than prescribed antidepressants. Depression is a lingering low, sad or hopeless mood, while anxiety mainly involves overwhelming feelings of worry, nervousness and fear. However, both conditions can also involve irritability, fatigue, sleep problems and difficulty concentrating (Kimberly Holland, 2022) A study published in June 2018 conducted an RCT with 103 participants who had treatment resistant depression to compare the effects of Ketamine infusion versus midazolam on depressive symptoms. The study found that ketamine infusion was significantly more effective than midazolam in reducing depressive symptoms at 24 hours and one week after treatment. The study also reported that ketamine infusion was safe and did not cause persistent dissociative or psychotomimetic effects (Kendra Cherry, 2023) Another Study published in August 2020 conducted a systematic review of 23 RCTs that evaluated the effects of psychedelics and other psychoplastogens for treating mental illness. The study found that psychedelics such as psilocybin, ketamine, MDMA (also known as ecstasy) and ayahuasca were more effective than traditional antidepressants in reducing symptoms of depression, anxiety, PTSD and substance use disorder (Johansen L, Liknaitzky P, Nedeljkovi, M et al, 2022). Finally a study in November 2020 conducted an RCT with 24 participants with major depressive disorder to test the efficacy and safety of psilocybin assisted therapy. The study found that two doses of psilocybin, given in conjunction with supportive psychotherapy produced rapid and large reductions in depressive symptoms that were sustained for at least a month. The study also reported that psilocybin was well tolerated and did not cause serious adverse events (John Hopkins medicine, 2020). REFERENCES https://www.beyondblue.org.au/media/statistics https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release Depression and Anxiety: How to Cope with Both, Differences, and More (healthline.com) https://www.healthline.com/health/mental-health/depression-and-anxiety by Kimberly Holland and Crystal Raypole,January 19, 2022 https://www.verywellmind.com/psychedelic-therapy-how-does-it-work-5079161 Johansen, L., Liknaitzky, P., Nedeljkovic, M. et al. The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol. Syst Rev 11, 85 (2022) https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows